Hoffman D C
Neurogen Corporation, Branford, CT 06405.
Pharmacol Biochem Behav. 1994 Apr;47(4):907-12. doi: 10.1016/0091-3057(94)90295-x.
The noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 prevents the development of sensitization to the locomotor-activating effects of amphetamine. In the present study, the possibility that the NMDA receptor might also play a role in the rewarding effects of amphetamine (as measured in the conditioned place preference paradigm) was investigated. Male Sprague-Dawley rats received amphetamine (2.0 mg/kg IP) paired with one side of a two-compartment box and saline paired with the other side. During these pairings locomotor activity was measured. On the test day, the amount of time drug-free rats spent in each compartment was determined. Rats trained with amphetamine alone showed a significant increase in time spent on the drug-paired side from pre- to postconditioning, indicating a place preference. When rats were injected with MK-801 (0.03, 0.1, or 0.3 mg/kg SC) prior to amphetamine, no significant effects on amphetamine place conditioning were observed. Rats treated with MK-801 alone showed significant place conditioning, but only at the intermediate dose. On conditioning days, MK-801 produced a dose-dependent enhancement of amphetamine-induced locomotor activity; however, MK-801 alone caused a similar increase in activity. The preferential D2 dopamine receptor antagonist eticlopride (0.01, 0.05, or 0.1 mg/kg SC) significantly reduced amphetamine locomotor activity, and the highest dose blocked place conditioning. These data suggest that the NMDA receptor is not involved in either the rewarding or locomotor-activating effects of amphetamine.
非竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂MK-801可防止对苯丙胺运动激活作用产生敏化。在本研究中,探讨了NMDA受体是否也可能在苯丙胺的奖赏效应中发挥作用(如在条件性位置偏爱范式中所测量的)。雄性Sprague-Dawley大鼠接受与双隔箱一侧配对的苯丙胺(2.0mg/kg腹腔注射)和与另一侧配对的生理盐水。在这些配对过程中测量运动活性。在测试日,测定无药物大鼠在每个隔室中花费的时间。仅用苯丙胺训练的大鼠在条件训练前后在药物配对侧花费的时间显著增加,表明有位置偏爱。当大鼠在注射苯丙胺前注射MK-801(0.03、0.1或0.3mg/kg皮下注射)时,未观察到对苯丙胺位置条件化有显著影响。单独用MK-801处理的大鼠显示出显著的位置条件化,但仅在中等剂量时。在条件训练日,MK-801产生剂量依赖性地增强苯丙胺诱导的运动活性;然而,单独使用MK-801也引起类似的活性增加。选择性D2多巴胺受体拮抗剂依托必利(0.01、0.05或0.1mg/kg皮下注射)显著降低苯丙胺的运动活性,且最高剂量可阻断位置条件化。这些数据表明,NMDA受体不参与苯丙胺的奖赏或运动激活作用。